Resource Category
Training Materials

FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs

Posted 2/28/2023 (updated 3/27/2024)

In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals should be cautious of possible xylazine inclusion in other substance overdoses and are strongly encouraged to report events in humans associated with xylazine exposure.